← All trials
NCT05950932
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2023
- Primary completion
- Mar 31, 2024
- Completion date
- May 31, 2024
- First posted
- Jul 18, 2023
- Last posted
- Jul 18, 2023
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Urbino "Carlo Bo"Lead sponsor
- University of PaviaCollaborator
- University of Urbino "Carlo Bo"Reponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.